JP2024517618A5 - - Google Patents
Info
- Publication number
- JP2024517618A5 JP2024517618A5 JP2023563172A JP2023563172A JP2024517618A5 JP 2024517618 A5 JP2024517618 A5 JP 2024517618A5 JP 2023563172 A JP2023563172 A JP 2023563172A JP 2023563172 A JP2023563172 A JP 2023563172A JP 2024517618 A5 JP2024517618 A5 JP 2024517618A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- optionally
- lymphoma
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174818P | 2021-04-14 | 2021-04-14 | |
| US63/174,818 | 2021-04-14 | ||
| US202163215760P | 2021-06-28 | 2021-06-28 | |
| US63/215,760 | 2021-06-28 | ||
| US202163288078P | 2021-12-10 | 2021-12-10 | |
| US63/288,078 | 2021-12-10 | ||
| US202263329560P | 2022-04-11 | 2022-04-11 | |
| US63/329,560 | 2022-04-11 | ||
| PCT/US2022/024725 WO2022221478A1 (en) | 2021-04-14 | 2022-04-14 | Binding proteins recognizing ha-2 antigen and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517618A JP2024517618A (ja) | 2024-04-23 |
| JP2024517618A5 true JP2024517618A5 (cg-RX-API-DMAC7.html) | 2025-04-22 |
Family
ID=83640691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563172A Pending JP2024517618A (ja) | 2021-04-14 | 2022-04-14 | Ha-2抗原を認識する結合タンパク質及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197877A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4322971A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024517618A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230170704A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2022204581B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023021034A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215276A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307429A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023012111A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202313670A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022221478A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024118640A2 (en) * | 2022-11-29 | 2024-06-06 | Bluesphere Bio, Inc. | T cell receptors targeting minor histocompatibility antigen ha-2 |
| WO2024148212A2 (en) * | 2023-01-06 | 2024-07-11 | The Trustees Of The University Of Pennsylvania | T cell receptors directed to sox2 protein |
| KR20260013471A (ko) | 2023-05-18 | 2026-01-28 | 클레이드 쎄라퓨틱스 인코포레이티드 | 세포 치료법에 대한 자연살해세포 세포독성 억제 |
| WO2025217028A1 (en) * | 2024-04-08 | 2025-10-16 | Tscan Therapeutics, Inc. | Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof |
| WO2025217035A2 (en) * | 2024-04-08 | 2025-10-16 | Tscan Therapeutics, Inc. | Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds |
| WO2026122679A1 (en) * | 2024-12-06 | 2026-06-11 | Tscan Therapeutics, Inc. | Binding proteins recognizing cd45 immunogenic peptides and uses thereof |
| WO2026128475A1 (en) | 2024-12-09 | 2026-06-18 | Century Therapeutics, Inc. | Genetically engineered induced pluripotent stem cells and effector cells derived therefrom |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318842T1 (de) * | 1995-07-25 | 2006-03-15 | Univ Leiden | Antigenische ha-2 peptide |
| WO2003054152A2 (en) * | 2001-12-10 | 2003-07-03 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| ES2635335T3 (es) * | 2010-09-20 | 2017-10-03 | Biontech Cell & Gene Therapies Gmbh | Receptores de células T específicos de antígeno y epítopos de células T |
| SI2755997T1 (sl) * | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| KR20190062505A (ko) * | 2016-10-03 | 2019-06-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Hpv-특이적 결합 분자 |
| AU2018234830B2 (en) * | 2017-03-15 | 2023-03-02 | Fred Hutchinson Cancer Center | High affinity MAGE-A1-specific TCRs and uses thereof |
| CN112566698A (zh) * | 2018-04-05 | 2021-03-26 | 朱诺治疗学股份有限公司 | T细胞受体和表达该t细胞受体的工程化细胞 |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| BR112021017744A2 (pt) * | 2019-03-08 | 2021-11-16 | Obsidian Therapeutics Inc | Composições e métodos de cd40l para regulação ajustável |
| US20220213167A1 (en) * | 2019-05-03 | 2022-07-07 | Gigamune, Inc. | Engineered cells expressing anti-tumor t cell receptors and methods of use thereof |
-
2022
- 2022-04-14 BR BR112023021034A patent/BR112023021034A2/pt unknown
- 2022-04-14 EP EP22788902.9A patent/EP4322971A4/en active Pending
- 2022-04-14 JP JP2023563172A patent/JP2024517618A/ja active Pending
- 2022-04-14 AU AU2022204581A patent/AU2022204581B2/en active Active
- 2022-04-14 KR KR1020237038120A patent/KR20230170704A/ko active Pending
- 2022-04-14 MX MX2023012111A patent/MX2023012111A/es unknown
- 2022-04-14 CA CA3215276A patent/CA3215276A1/en active Pending
- 2022-04-14 IL IL307429A patent/IL307429A/en unknown
- 2022-04-14 WO PCT/US2022/024725 patent/WO2022221478A1/en not_active Ceased
- 2022-04-14 US US18/286,726 patent/US20240197877A1/en active Pending
- 2022-04-14 TW TW111114218A patent/TW202313670A/zh unknown
-
2023
- 2023-07-13 AU AU2023204645A patent/AU2023204645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021200388B2 (en) | Methods of isolating T cell receptors having antigenic specificity for a cancer specific mutation | |
| US12391742B2 (en) | Anti-KRAS-G12D T cell receptors | |
| JP7270001B2 (ja) | Mhcクラスii拘束性mage-a3を認識するt細胞受容体 | |
| Beyar-Katz et al. | Novel approaches to acute myeloid leukemia immunotherapy | |
| JP2023549765A5 (cg-RX-API-DMAC7.html) | ||
| JP7770188B2 (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| MacDonald et al. | Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor | |
| Behar et al. | Diverse TCRs recognize murine CD1 | |
| Mingari et al. | HLA-class I-specific inhibitory receptors in human cytolytic T lymphocytes: molecular characterization, distribution in lymphoid tissues and co-expression by individual T cells. | |
| JP2023534808A (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| CA3144070A1 (en) | T cell receptors recognizing r175h or y220c mutation in p53 | |
| CN115747156A (zh) | 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖 | |
| US12365717B2 (en) | Specific t cell receptors against epitopes of mutant MYD88L265P protein for adoptive T cell therapy | |
| JP2024546018A5 (cg-RX-API-DMAC7.html) | ||
| JP2024515646A5 (cg-RX-API-DMAC7.html) | ||
| Jaigirdar et al. | A high avidity WT1 reactive T cell receptor mediates recognition of peptide and processed antigen but not naturally occurring WT1 positive tumor cells | |
| Zambello et al. | Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes | |
| Chen et al. | Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system | |
| AU2016329542C1 (en) | TCR and uses thereof | |
| JP2025516264A5 (cg-RX-API-DMAC7.html) | ||
| Chmielowski et al. | In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities | |
| TW202406569A (zh) | 多重t細胞受體組合物、組合療法及其用途 | |
| US20240360236A1 (en) | Methods for targeted immunotherapy of acute myeloid leukemia (aml) | |
| EP4491630A1 (en) | T-cell receptor for acute myeloid leukemia (aml) | |
| EP4223782A1 (en) | Novel t cell receptors and immune therapy using the same for the treatment of cancer |